Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine

Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, Stefan Faderl, Susan O'Brien, Amber Fullmer, Jorge E. Cortes, William Wierda, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Background: Myelodysplastic syndromes (MDS) progress to acute myeloid leukemia (AML) in approximately 30% of patients. Identification of risk factors for progression to AML and overall survival (OS) would help guide treatment decisions. Patients and Methods: We investigated prognostic factors for progression to AML and survival in 163 patients with MDS treated with decitabine 15 mg/m2 over 3 hours every 8 hours for 3 days every 6 weeks (n = 74) or 20 mg/m2 over 1 hour daily for 5 days every 4 weeks (n = 89). Results: Multivariate analysis of pooled baseline data revealed that only study effect was associated with progression to AML. A hemoglobin value at least 10 g/dL, platelet count at least 50 × 103/μL, and lack of chromosome 5 or 7 abnormalities were associated with longer OS. Conclusions: Patients with certain prognostic factors should be considered for other interventions in addition to decitabine treatment.

Original languageEnglish (US)
Pages (from-to)131-138
Number of pages8
JournalClinical Lymphoma, Myeloma and Leukemia
Volume13
Issue number2
DOIs
StatePublished - Apr 1 2013
Externally publishedYes

Fingerprint

decitabine
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Disease Progression
Survival
Chromosomes, Human, Pair 5
Chromosomes, Human, Pair 7
Platelet Count
Hemoglobins
Multivariate Analysis
Therapeutics

Keywords

  • Acute myeloid leukemia
  • chronic
  • Decitabine
  • Myelodysplastic syndromes
  • Myelomonocytic leukemia
  • Risk factors

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. / Jabbour, Elias; Garcia-Manero, Guillermo; Ravandi, Farhad; Faderl, Stefan; O'Brien, Susan; Fullmer, Amber; Cortes, Jorge E.; Wierda, William; Kantarjian, Hagop.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 13, No. 2, 01.04.2013, p. 131-138.

Research output: Contribution to journalArticle

Jabbour, Elias ; Garcia-Manero, Guillermo ; Ravandi, Farhad ; Faderl, Stefan ; O'Brien, Susan ; Fullmer, Amber ; Cortes, Jorge E. ; Wierda, William ; Kantarjian, Hagop. / Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. In: Clinical Lymphoma, Myeloma and Leukemia. 2013 ; Vol. 13, No. 2. pp. 131-138.
@article{5dcd4c02653d4c3992d99f07b562ee4d,
title = "Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine",
abstract = "Background: Myelodysplastic syndromes (MDS) progress to acute myeloid leukemia (AML) in approximately 30{\%} of patients. Identification of risk factors for progression to AML and overall survival (OS) would help guide treatment decisions. Patients and Methods: We investigated prognostic factors for progression to AML and survival in 163 patients with MDS treated with decitabine 15 mg/m2 over 3 hours every 8 hours for 3 days every 6 weeks (n = 74) or 20 mg/m2 over 1 hour daily for 5 days every 4 weeks (n = 89). Results: Multivariate analysis of pooled baseline data revealed that only study effect was associated with progression to AML. A hemoglobin value at least 10 g/dL, platelet count at least 50 × 103/μL, and lack of chromosome 5 or 7 abnormalities were associated with longer OS. Conclusions: Patients with certain prognostic factors should be considered for other interventions in addition to decitabine treatment.",
keywords = "Acute myeloid leukemia, chronic, Decitabine, Myelodysplastic syndromes, Myelomonocytic leukemia, Risk factors",
author = "Elias Jabbour and Guillermo Garcia-Manero and Farhad Ravandi and Stefan Faderl and Susan O'Brien and Amber Fullmer and Cortes, {Jorge E.} and William Wierda and Hagop Kantarjian",
year = "2013",
month = "4",
day = "1",
doi = "10.1016/j.clml.2012.11.001",
language = "English (US)",
volume = "13",
pages = "131--138",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "2",

}

TY - JOUR

T1 - Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine

AU - Jabbour, Elias

AU - Garcia-Manero, Guillermo

AU - Ravandi, Farhad

AU - Faderl, Stefan

AU - O'Brien, Susan

AU - Fullmer, Amber

AU - Cortes, Jorge E.

AU - Wierda, William

AU - Kantarjian, Hagop

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Background: Myelodysplastic syndromes (MDS) progress to acute myeloid leukemia (AML) in approximately 30% of patients. Identification of risk factors for progression to AML and overall survival (OS) would help guide treatment decisions. Patients and Methods: We investigated prognostic factors for progression to AML and survival in 163 patients with MDS treated with decitabine 15 mg/m2 over 3 hours every 8 hours for 3 days every 6 weeks (n = 74) or 20 mg/m2 over 1 hour daily for 5 days every 4 weeks (n = 89). Results: Multivariate analysis of pooled baseline data revealed that only study effect was associated with progression to AML. A hemoglobin value at least 10 g/dL, platelet count at least 50 × 103/μL, and lack of chromosome 5 or 7 abnormalities were associated with longer OS. Conclusions: Patients with certain prognostic factors should be considered for other interventions in addition to decitabine treatment.

AB - Background: Myelodysplastic syndromes (MDS) progress to acute myeloid leukemia (AML) in approximately 30% of patients. Identification of risk factors for progression to AML and overall survival (OS) would help guide treatment decisions. Patients and Methods: We investigated prognostic factors for progression to AML and survival in 163 patients with MDS treated with decitabine 15 mg/m2 over 3 hours every 8 hours for 3 days every 6 weeks (n = 74) or 20 mg/m2 over 1 hour daily for 5 days every 4 weeks (n = 89). Results: Multivariate analysis of pooled baseline data revealed that only study effect was associated with progression to AML. A hemoglobin value at least 10 g/dL, platelet count at least 50 × 103/μL, and lack of chromosome 5 or 7 abnormalities were associated with longer OS. Conclusions: Patients with certain prognostic factors should be considered for other interventions in addition to decitabine treatment.

KW - Acute myeloid leukemia

KW - chronic

KW - Decitabine

KW - Myelodysplastic syndromes

KW - Myelomonocytic leukemia

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=84877314620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877314620&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2012.11.001

DO - 10.1016/j.clml.2012.11.001

M3 - Article

C2 - 23260600

AN - SCOPUS:84877314620

VL - 13

SP - 131

EP - 138

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - 2

ER -